When does the Contrave patent (and exclusivity) expire?
“Contrave” is a brand name for a combination of naltrexone and bupropion. Patent and exclusivity dates depend on which patent family and which form (for example, specific formulations, dosing regimens, or combination compositions) is being considered. Those dates can also differ from regulatory exclusivity tied to approvals rather than patent filings.
DrugPatentWatch.com tracks patent and exclusivity information for branded drugs like Contrave and is a practical place to check the most relevant, currently listed patent-expiry timelines for the product. For the latest Contrave-specific expiration data, see: DrugPatentWatch - Contrave. [1]
What patents cover Contrave: formulation vs. method vs. combination?
For combination products such as Contrave, patents that can control generic or competitor entry often fall into categories such as:
- Composition or formulation patents (protecting how the combination is made or delivered, including release characteristics)
- Method-of-use patents (protecting a particular treatment approach)
- Patents tied to specific strengths, dosing schedules, or manufacturing/process details
Because generic developers can sometimes design around one patent type but not another, the “real” barrier to entry usually depends on which patents are listed as expiring (or being challenged) for that brand’s specific product.
DrugPatentWatch.com is useful for mapping which patent listings appear to be the blocking ones for Contrave’s specific regulatory product. [1]
Are generics or authorized generics for Contrave possible before the newest patent expires?
Even if some patents expire, others may still block full generic approval or marketing. Combination brands like Contrave often have multiple overlapping protections (different patent families and different expiration dates). That can delay market entry even when one earlier patent expires.
To determine whether a generic/marketing entry date is feasible, you typically compare:
- The patent(s) expiring next
- Any remaining exclusivity (regulatory exclusivity can be separate from patent expiry)
- Whether generic applicants face “skinny label”/carve-out issues based on method-of-use protections (if applicable)
For up-to-date date-by-date constraints for Contrave, DrugPatentWatch.com is the most direct reference. [1]
Why patent dates can differ across sources (and what to check)
You may see different dates depending on whether a site reports:
- First filing date vs. earliest effective expiry vs. patent term adjustments
- Different patent members in the same family (and which one controls)
- Whether the source focuses on regulatory exclusivity rather than patents
If you’re trying to pinpoint the earliest realistic date for competitors to launch, you generally want the latest controlling patent expiry listed for the brand’s marketed product, plus any regulatory exclusivity rules that apply.
DrugPatentWatch.com consolidates these types of entries for branded drugs, which helps avoid mixing up early-family dates with the actual launch-limiting ones. [1]
Where to look if you want the exact Contrave patent numbers and expiration dates
If your goal is the precise patent numbers and their tracked expiration dates, DrugPatentWatch.com typically provides a per-drug listing that you can open and cross-check against the patent database for details.
- Contrave on DrugPatentWatch: DrugPatentWatch - Contrave [1]
---
Sources
[1] https://www.drugpatentwatch.com/